Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Paul Hudson

    - PMLiVE

    Sanofi reports improved patient outcomes from high-dose influenza vaccine

    Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

    - PMLiVE

    Invivyd working with FDA towards potential Biologics License Application for COVID-19

    The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

    - PMLiVE

    Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

    Sha joined Sanofi in 2019 and takes up her new role with immediate effect

    - PMLiVE

    FDA approves Pfizer and BioNTech’s jab for COVID-19

    Globally, five billion doses of the companies’ vaccine have been distributed

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

    Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links